Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_assertion type Assertion NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_head.
- NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_assertion description "[Compared with those with low GADA titers, patients with high GADA titers had more prominent traits of insulin deficiency and a profile of more severe autoimmunity resulting in higher A1C, lower BMI, a lower prevalence of metabolic syndrome and its components (P < 0.02 for all), a higher prevalence of IA-2As, TPO antibodies (P < 0.003 for both), and DRB1*03-DQB1*0201 (50 vs. 26.8%, P = 0.001), and a decreasing frequency of DQB1*0602 and DRB1*0403 (from type 2 to low and to high GADA titer autoimmune diabetes; P < 0.001 for trend for both comparisons).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_provenance.
- NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_assertion evidence source_evidence_literature NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_provenance.
- NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_assertion SIO_000772 17392553 NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_provenance.
- NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_assertion wasDerivedFrom befree-2016 NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_provenance.
- NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_assertion wasGeneratedBy ECO_0000203 NP601502.RA591V4RFxM3DLzhFI9LAA_XBez_FDWnQlm5ms0kd3CLg130_provenance.